- A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER)Zhang, L.; Fang, W.; Yu, Q.; Zhang, H.; Wu, G.; Wu, D.; Lin, Y.; Zhu, J.; Chen, J.; Hu, X.; Lan, B.; Zhou, Z.; Lin, H.; Wang, Z.; Lei, X.; Pan, S.; Chen, L.; Zhang, J.; Kong, T.; Yu, H.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
- Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatmentYuman, Yu; Yuehong, Wang; Linying, Wu; Xuanli, Xu; Hua, Zhou; Qing, Wang; Jianying, ZhouMedicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2021, 100(5): e23712.
- Phase 1b study of HS-10241 combined with almonertinib in pre-treated advanced nonsmall cell lung cancer (NSCLC) harboring EGFR mutationDong, Xiaorong; Chen, Jianhua; Yu, Yan; Hu, Jie; Li, Xingya; Cheng, Ying; Yao, Wenxiu; Hu, Yanping; Wang, Qiming; Lu, Junguo; Zheng, Wei; Yu, Xinmin; Zhang, Peng; Yu, Zhuang; Wei, Hongying; Li, Chuan; Huang, Qiqi; Tao, Mengyuan; Wu, Qiong; Lu, ShunAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trial
15阅读
